During concurrent use , patients should contact their healthcare provider if they experience: Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) Severe, persistent abdominal pain (often radiating to the back) with or without vomitingthis could indicate pancreatitis, a serious adverse effect associated with GLP-1 receptor agonists requiring urgent medical evaluation Unexplained fatigue, jaundice, or abdominal pain (potential liver concerns) Worsening gastrointestinal symptoms beyond typical semaglutide side effects New or unusual symptoms that may represent an adverse reaction Patients taking oral medications with a narrow therapeutic index should discuss timing and monitoring with their healthcare provider, as semaglutide's effect on gastric emptying may affect absorption
Reducing oxidative stress Research in Cell Reports shows that GLP-1 medications decrease oxidative stress, thereby protecting organs and tissues from inflammation-related damage
Setting Realistic Expectations Counsel patients that plateaus are normal and that weight maintenance represents therapeutic success, not failure
Compounded drug products are not FDA-approved.Required Actions: Within 15 days, the company must respond in writing to the Office of Compounding Quality and Compliance (OCQC) with a description of how the company has addressed the violations, including removal of misleading language
For related considerations, see GLP-1 and breastfeeding
